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URINE MICROSCOPY FINDINGS PREDICT OUTCOMES IN HOSPITALIZED 
PATIENTS WITH ACUTE KIDNEY INJURY 
Patricia R. Peter, Isaac E. Hall, Steven G. Coca, and Chirag R. Parikh.  Section of 
Nephrology, Department of Internal Medicine, Yale University School of Medicine, New 
Haven, CT 
 
Though urine microscopy has long been highly regarded by nephrologists as an essential 
diagnostic tool, its potential utility in predicting outcome in acute kidney injury (AKI) 
warrants further exploration.  In this study, urine sediment microscopy was performed on 
165 hospitalized patients on the first day of their clinical AKI diagnosis to determine 
whether microscopy findings early in the course of this disease correlate with 
“worsening,” a composite of increasing AKI stage and in-hospital mortality.  Microscopy 
findings were recorded as individual cells and casts along with a microscopy score 
derived from renal tubular epithelial (RTE) cells and granular casts.  Our data suggest 
that both increasing numbers of granular casts and a higher microscopy score are 
predictive of overall worsening (p = 0.027 and p = 0.046, respectively), but other 
microscopy features such as the number of RTE cells are not.  These data demonstrate 
that urine microscopy even at the time of initial diagnosis can be predictive of eventual 
outcome, potentially serving as a useful adjunct to clinical and other biochemical data in 
the study of AKI.   
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Uroscopy: Early Physicians and the Art of Looking at Urine  
As urine was one of the most readily available and easily accessible bodily fluids, 
early physicians and scientists focused their efforts on gleaning all the information they 
could about the mysterious workings of the human body by noting the physical 
characteristics of urine, a process known as uroscopy.  Though ancient Sanskrit and 
Sumerian texts indicate that several ancient civilizations were making important 
observations about the properties of urine, it is the Greeks and Hippocrates, in particular, 
who are often credited with being the first uroscopists (1).  Hippocrates’ treatise, 
Prognostics,  became one of the most widely propagated texts on the subject of uroscopy, 
delineating the properties of urine that would be studied for many centuries to follow 
including its color (white, red, black), consistency (thin, thick, watery, clear, cloudy), 
sediment (smooth, leafy, farinaceous, absent), odor (fetid), and volume (deficient) (2).  
Hippocrates’ initial observations were later expanded by the Roman physician Galen who 
believed that the study of the urine was an important means of determining the relative 
balance of the four humors (blood, phlegm, yellow and black bile), which he 
hypothesized were the determinants of disease (2).   
By the 13th century, uroscopy was a well-established field and efforts were being 
made to improve its scientific accuracy.  In order to view the urine more clearly and to 
more accurately describe its properties, physicians debated the appropriate characteristics 
of the vessel in which urine should be stored.  Since it was believed that urine would 
behave most physiologically in a receptacle that was bladder-shaped, the matula was 
born, a clear glass vessel with a rounded-bottom that was held up to the light for best 
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inspection of the urine held within (1).  Uroscopy had become so entrenched in the 
practice of medicine that soon after the matula was introduced into common practice, it 
quickly became the symbol of the Medieval physician and was widely depicted in art of 
the time (2).  The matula itself would undergo many changes throughout the centuries, 
gradually acquiring increasing layers of complexity.  In fact, by the 16th century, the 
matula had become human-body shaped and had been subdivided into twenty-four levels 
in an effort to improve the precision of diagnosis.  It was thought that the urine vapors 
would congregate into the level corresponding to the diseased body part (2).   
In fact, so much store was set in the powerful diagnostic value of uroscopy that by 
the 14th century, it quickly became subject to much abuse.  Charlatans began dabbling in 
the art of uroscopy, recognizing its moneymaking potential.  These unscrupulous quacks 
would offer to analyze the urine of their unsuspecting public, come to an outrageous 
diagnosis, and offer their now terrified ‘patient’ an incredibly expensive ‘cure’(2).  
Ironically, physicians were in no small part contributing to this behavior.  As their 
confidence in their uroscopy skills grew, physicians began claiming that physical 
examination of the patient had been rendered unnecessary as all necessary diagnostic 
information could be obtained by examination of the urine (2).  Textbooks on uroscopy 
became available to the general public so that people began diagnosing and treating 
themselves after observing the characteristics of their own urine (1).  By the late 16th 
century, the excesses of the field had grown to such a degree that ‘uromancy’ was born 
which focused on divining the future from examination of the urine (1).   
In response to these excesses, the 16th century saw a backlash against the practice 
of examining urine in diagnostic medicine.  Author Thomas Brian wrote Pisse Prophet in 
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1637,  a scathing attack on uroscopy which quickly made the matula and physicians who 
used it the subject of much ridicule and scorn (1).  Thomas Linacre, the founding 
president of the College of Physicians in England, instituted a statute preventing 
physicians from continuing the practice of examining urine in lieu of examining their 
patients, and members of the college began producing works that favored a more 
measured view of the benefits and limits of uroscopy (2).  The Enlightenment’s focus on 
rationality and science helped shift the focus of uroscopy from the observable physical 
characteristics of urine to a more sophisticated biochemical analysis of urine’s 
components, a shift that would be aided immensely by the invention of the microscope.   
A Brief History of Urine Microscopy 
 
Though the first observation of the urine with the aid of a microscope was likely 
performed in the 17th century, technology at the time was rudimentary at best and so the 
analyses possible at that time were also.  Early uses of microscopy focused on the study 
of kidney stones as this was a disease of the rich and one in which microscopic analysis 
of the urine for stone precursors was thought to be quite promising (3).  Urine 
microscopy remained quite limited until the first half of the 19th century when advances 
in the technology and availability of microscopes made it possible for the field of urine 
microscopy to grow and begin to contribute to our understanding of renal pathology. 
   Three Frenchmen share the distinction of being some of the earliest physicians to 
perform sophisticated analyses of urine via microscopy: Pierre Rayer, a physician at 
l’Hôpital de la Charité in Paris, his intern, Eugène Vigla, and their contemporary and 
academic rival, Alfred Donné (4).  Though Donné published some of the first 
daguerrotypes of the microscopic elements of urine, it was truly Rayer and Vigla who 
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more methodically described and more clearly articulated the potential clinical 
implications of their findings (3).  Their extensive findings were initially published in the 
French journal l’Expérience in 1835 before being included in a comprehensive textbook 
Traité des maladies des reins (4).  Rayer and Vigla developed the first standards of how 
to properly handle urine and identified important microscopic constituents of urine 
including crystals, squamous cells, mucus, pus, blood, lipids, sperm, yeast, and possibly 
even casts (4).  They also began to recognize and describe the microscopic appearance of 
clinical syndromes, recognizing the potential utility of microscopy in clinical nephrology.  
For example, they noted that in acute nephritis there was often a collection of blood, 
mucus, squamous cells, and fibrin in the urine while in nephrotic syndrome they 
described thin lamellae of amorphous substance (possibly casts), mucus, lipids, blood, 
and uric acid crystals (5).  Thus, even when in its infancy, urine microscopy was found to 
have observable patterns that not only correlated with clinical findings but could perhaps 
be instrumental in differentiating between clinical syndromes.   
 These early advances in France led to a wave of discovery in England and 
Germany, the leading scientific nations at the time.  Johann Simon in Germany focused 
on casts, recognizing them as different in character and appearance from other cells in the 
urine.  He and other German scientists Julius Vogel and Hermann Nasse first understood 
that the casts they were identifying were derived from the tubular epithelium (4).  
Meanwhile, in England, Golding Bird published Urinary deposits. Their diagnosis, 
pathology, and therapeutical indications in 1844, a work that expanded on many of the 
findings of his French colleagues and introduced microscopy to the English scientific 
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community (4).  Bird’s work was limited in that its primary focus was on crystals with 
only one chapter focusing on the noncrystalline elements of urine (3).   
 The second half of the 19th century saw further improvements in the technology of 
lenses, leading to improved image quality and thus, to further advances in the field of 
urine microscopy.  The concept of staining was also being introduced to the field at this 
time, a key development that would allow the Italian scientist Carlo Rovida to make the 
observation that casts were composed of a unique protein which would only be identified 
almost a century later (3). Centrifugation of the urine sample prior to microscopy also 
became standard practice, ensuring that all the salient features of the sediment were 
captured and examined.  By the end of the century, atlases were published around the 
world carefully detailing the typical urine sediment found in different renal diseases and 
urine microscopy was beginning to be incorporated in medical school curricula in North 
America, signs that urine microscopy was becoming a well-established part of clinical 
practice. 
 In the 20th century, urine microscopy as practiced today was perfected.  In the 
1920s the Scottish-American Thomas Addis did his famous studies on his 
glomerulonephritis patients, following their urines serially and noting that their sediment 
findings would become blander as their disease transitioned from the acute phase to the 
chronic.  He also developed his own method of quantifying urine microscopy findings 
using collection of timed urine and counting chambers, a method that would eventually 
be named after him and which is still in use today (3). With this method, Addis was able 
to describe ‘renal failure casts,’ broad casts that were found in extremely high quantities 
in the urine of patients who were dying of uremia (6).  
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Table 1 Urinalysis findings in renal disease 
The latter half of the 20th century saw 
the introduction of new types of microscopy 
to the study of the urine, including 
immunofluorescence, transmission electron 
microscopy and phase contrast, the first of 
which would be instrumental in the 
identification of Tamm-Horsfall glycoprotein 
in the matrix of casts (9).  Phase contrast 
microscopy was quickly recognized as far 
superior to its predecessor, as it allowed for 
more precise visualization of structures in the 
sediment (10).  In the 1980s, interest in urine 
microscopy was renewed when Fairley and 
colleagues noted that the morphology of 
RBCs could be a useful key to distinguishing 
glomerular from non-glomerular hematuria (11).   
Component Clinical significance
Cellular  
Eosinophils AIN, atheroembolic disease, 
pyelonephritis, glomerular 
disease 
Granulocytes infection, nephritis 




RTE cells AKI, AIN, glomerular disease 
Uroepithelial 
cells 
neoplasia, stones, UTI 
Casts  
Hyaline non-specific, normal finding 
Granular ATN 
Waxy chronic renal impairment 
Fatty nephrotic syndrome 
RBC casts glomerular disease 
WBC casts AIN, pyelonephritis, 
glomerular disease 
RTE cell casts ATN, AIN, nephrotic 
syndrome, glomerular disease 
Other  
Lipids nephrotic syndrome 
Bacteria infection 
Crystals inherited metabolic disorders, 
toxins 
AIN = allergic interstitial nephritis; UTI = urinary tract 
infection                                                      
Adapted from DeLanghe 2000 (7) and Fogazzi 2011 (8) 
Thus, the study of the urine, whether with the eye as in ancient times or more 
recently with the aid of microscopy, has always played been an important role in 
improving our understanding of renal diseases.  As a result of the work of these 
pioneering scientists and physicians, sophisticated interpretation of urinalysis is now 
routine and serves a useful tool in the diagnosis of kidney pathology (see Table 1). 
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Limitations of Urine Microscopy and Future Directions 
Despite its well-established place as a diagnostic tool in the field of nephrology, 
urine microscopy does not come without its limitations, most of which have been well-
documented (7).  Primary among these limitations is the considerable variability inherent 
in the technique in everything from how samples are prepared to who or what is 
analyzing them.  A study by Winkel et al in 1978 methodically explored many of these 
sources of error, concluding that the greatest source of error lay in sample preparation, 
especially in centrifugation (12, 13). 
In addition to questions of how best to prepare and handle samples, there has been 
some debate as to the best means of quantifying urine sediment findings.  The typical 
method involves counting the number of cells per high power field (HPF) which is a 
lower cost and less labor intensive method than chamber counting, a more quantitative 
technique which allows for identifying cellular elements per mL of sample.  One study by 
Kesson et al showed that in a series of 88 duplicate urines, abnormal numbers of casts or 
white or red blood-cells were detected by the quantitative method in 74% of patients with 
abnormal renal function but in only 36% by the HPF method (14).  Though it is known 
that urine sediment findings are imprecisely recorded with the HPF method, current 
guidelines still recommend this method over chamber counting because its ease of use 
and low cost make it much more feasible in daily practice (15).    
Another much noted source of considerable error is of course interobserver 
variability. A study by Tsai et al found that this variability could potentially have a 
significant impact on a physician’s ability to make the proper diagnosis.  Urine samples 
were taken from 26 patients diagnosed with acute kidney injury (AKI) who were seen by 
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the nephrology consultation service.  These samples were independently analyzed by a 
nephrologist (nephrologist A) and by the hospital laboratory technicians.  Nephrologist A 
correctly diagnosed the cause of AKI in 24 patients (92%) after his examination of the 
urine while nephrologist B, given only the laboratory UA report, was correct only 5 times 
(19%), improving to 69% (18 patients) after reviewing nephrologist A’s UA report.  Both 
nephrologists were blinded to the patient’s clinical history.  Significant differences 
existed between nephrologist A’s microscopy report compared with the clinical 
laboratory’s report with nephrologist A reporting a higher number of RTE cells (P < 
0.0001), granular casts (P = 0.0017), hyaline casts (P = 0.0233), and RTE casts (P = 
0.0008).  There were no significant differences in the reporting of other urinary 
sediments, including WBCs, WBC casts, RBCs, RBC casts, transitional epithelial cells, 
oval fat bodies, bacteria, yeast, and crystals (16).  These findings argue for the 
importance of relying on trained observers in analyzing urine microscopy.  However, as 
shown recent study by Wald et al., interobserver variability can be significant even 
amongst highly trained nephrologists.  Ten nephrologists of different levels of experience 
were asked to identify structures in the microscopy images of 86 patients who had been 
seen by the nephrology service.  Using the ĸ statistic to determine the level of agreement, 
they found that squamous epithelial cells (κ = 0.54) and hyaline casts (κ = 0.52) had the 
highest levels of interobserver agreement, while identification of transitional epithelial 
cells (κ = 0.14) and fatty casts (κ = 0.06) had the lowest levels. They also measured 
overall agreement in the presence or absence of a structure, finding that complete 
agreement for most types of casts was generally better (59%-79%) than for most cellular 
elements (31%-39%) with the notable exception of coarse and fine granular casts (32% 
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and 37%, respectively) (17).  Thus, even in identification of simple cellular elements, 
measurable and significant variability can exist between trained observers.   
Different types of microscopy also offer their own advantages and disadvantages.  
Though traditional bright field microscopy is easiest and often most commonly used, its 
relatively poor visualization capabilities make it difficult to distinguish bacteria from 
amorphous debris or leukocytes from small tubular cells (10).  In fact, all of the most 
recent urinalysis guidelines put out by Finnish, Japanese, and European societies note to 
the inadequacy of bright field microscopy even if accompanied by supravital staining, 
recommending phase contrast microscopy instead (10, 15).  
In an effort to minimize these potential sources of error and to improve 
standardization and reliability of urine microcopy results, there has been a move towards 
automated microscopy over manual microscopy in the field.  Several studies have shown 
that the automated systems currently in use (ie the Sysmex UF-100, sediMAX, and the 
Iris iQ200) are more precise than manual techniques in identifying cellular elements 
though not casts (18-21).  Even as technology evolves and automated identification of 
casts improves, nephrologists undoubtedly will continue to rely on a combination of 
automated and manual techniques to assist them in their study of renal diseases.      
Acute Kidney Injury: Definition, Pathophysiology and Clinical Features 
Acute kidney injury (AKI), formerly known as acute renal failure, affects 
somewhere between 2-18% of all hospitalized patients and as many as 25-30% of 
patients in the ICU (22).  Though it has been recognized as a disease entity since World 
War II, there had been as many as 35 different definitions of the disease in the literature 
until 2002 when the Acute Dialysis Quality Initiative (ADQI) sought to establish a 
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consensus definition to facilitate the production of more precise and accurate research on 
the subject (23).  They proposed the Risk, Injury and Failure, Loss of function and End-
stage kidney disease (RIFLE) staging system which defined three stages of severity of 
AKI (risk, injury, failure) based on serum creatinine (Scr) and urine output criteria and 
included two outcome criteria (loss and end-stage renal disease) based on duration of 
RRT therapy (22) (see Table 2).  Subsequent studies have indicated that even more 
modest changes in creatinine could lead to significant morbidity, prompting a re-
evaluation of the definition and staging system in 2005 by the Acute Kidney Injury 
Network (AKIN) (24-26) (see Table 2).  Though some recent studies have suggested that 
the new criteria have failed to show any improvement in predicting outcomes over the 
RIFLE criteria, the potential advantages of this new staging system have yet to be fully  
 
explored (27, 28).  
 
Table 2 RIFLE and AKIN staging systems 
  Criteria
  Serum creatinine Urine output Drop in GFRA 
RIFLE    
Risk ↑SCr ≥ 1.5 * baselineB <0.5ml/kg/h ≥ 6h ≥25% 
Injury ↑SCr ≥ 2.0 * baseline <0.5ml/kg/h ≥ 12h ≥50% 
Failure ↑SCr ≥ 3.0 * baseline or       
↑SCr ≥ 0.5mg/dL from baseline 
or SCr ≥ 4.0mg/dL 
<0.3ml/kg/h ≥ 24h or 
anuria ≥ 12h 
≥75% 
Loss Loss of kidney function >4wks   
ESRD Loss of kidney function >3mos     
AKIN    
Stage 1 ↑SCr ≥ 1.5 * baselineC or     
↑SCr ≥ 0.3mg/dL from baseline 
<0.5ml/kg/h ≥ 6h  
Stage 2 ↑SCr ≥ 2.0 * baseline <0.5ml/kg/h ≥ 12h  
Stage 3 ↑SCr ≥ 3.0 * baseline or       
↑SCr ≥ 0.5mg/dL from baseline    
or SCr ≥ 4.0mg/dL             
or initiation of RRT 
<0.3ml/kg/h ≥ 24h or 
anuria ≥ 12h 
 
A Only one of the three RIFLE criteria has to be fulfilled to qualify for a specific stage  
B Baseline SCr is considered to be within one week for RIFLE 
C Baseline SCr is considered to be within 48 hours for AKIN 
AKIN = Acute Kidney Injury Network; ESRD = End-stage renal disease; RIFLE = Risk, Injury, and Failure, Loss of 
function and ESRD; RRT = renal replacement therapy  
Table adapted from Lines 2009 (21) 
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The most common cause of AKI is ischemic injury, the pathogenesis of which has 
been clearly elucidated (29, 30).  The renal tubular epithelial cells of the kidney are 
susceptible to injury due to their blood supply located in the medulla, an area that is 
particularly prone to ischemia.  Once ischemic injury occurs, the cytoskeletal architecture 
of the renal tubular epithelial cells is disrupted, leading to a loss of cellular polarity and 
the shedding of the proximal tubule’s brush border.  During this initiation phase of AKI, 
though intracellular ATP depletion is severe, the injury to the endothelium remains 
sublethal and reversible, allowing for a complete recovery if the instigating insult is 
removed.  Tamm-Horsfall protein, normally secreted by the thick ascending limb as a 
monomer, becomes a gel-like polymer in the high sodium environment of the distal 
tubule where it can combine with the debris of injured cells and brush border membranes 
to form casts (30).  Casts and sloughed off cells obstruct the lumen, contributing to the 
kidney’s declining glomerular filtration rate (GFR).   
 During the extension phase of the injury, blood flow returning to the renal cortex 
leads to reperfusion-related cell death while continued vasoconstriction in the medulla 
contributes to further RTE cell death (30).  Leukocytes are recruited to the site of injury 
and produce inflammatory mediators and reactive oxygen species that worsen the cellular 
damage.  RTE cells also contribute to this deleterious response by secreting chemokines 
and cytokines that perpetuate the cycle of inflammation.   
During the maintenance phase, parenchymal injury is established and GFR 
reaches its nadir (30).  At this time, a balance is maintained between continued cell death 
and incipient attempts at cellular regeneration.  The process of cellular recovery involves 
dedifferation of viable cells followed by proliferation and eventual restoration of the 
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normal epithelium (30).  Finally, during the recovery phase of the injury, the GFR 
gradually improves as the integrity of the epithelial cells is restored.  Though the kidney 
has the capacity to fully and completely repair itself after sustaining this type of acute 
injury, a partial repair can generate a state of persistent inflammation in the kidney that 
can eventually manifest years later as end-stage renal disease (ESRD) (29).      
 The etiologies of AKI are typically divided into three categories: pre-renal, 
intrinsic, and post-renal.  Outside of the ICU, 55-60% of AKI is pre-renal, 35-40% is 
intrinsic and <5% is post-renal (31).  Determining the cause of AKI necessitates a 
diagnostic workup consisting of a history, a focused physical to assess volume status, 
basic laboratory tests including a BUN/Cr ratio, and imaging studies such as a renal 
ultrasound, if necessary.  Special attention is of course paid to examination of the urine, 
especially to the measurement of urine electrolytes (in particular the fractional excretion 
of sodium or FeNa) and to the analysis of the urine sediment via microscopy.  Together, 
these various aspects of the diagnostic workup can lead to a definitive diagnosis (see  
Table 3).  For example, an elevated BUN/Cr ratio with a FeNa < 1% and a bland urine  
Table 3 Urine studies in acute kidney injury 
  Hypovolemia ATN AIN Glomerulonephritis Obstruction








RBCs, RBC casts Bland or 
bloody 
Protein None or low None or 
low 
Minimal >100mg/dL Low 
Urine Na 
(mEq/L) 
<20 >30 >30 <20 <20 (acute)      
>40 (few days) 
Urine Osm 
(mOsm/kg) 
>400 <350 <350 >400 <350 
FeNa (%) <1 >1 Varies <1 <1 (acute) 
>1(few days) 
AIN = allergic interstitial nephritis; ATN = acute tubular necrosis; FeNa = fractional excretion of sodium; Na = 
Sodium; Osm = osmolality; RBC = red blood cell; WBC = white blood cell 
Table adapted from Singri 2003 (32) 
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sediment is highly suggestive of a pre-renal etiology.  If the AKI has progressed to acute 
tubular necrosis (ATN), the urine sediment often shows brownish granular casts with 
renal tubular epithelial cells.  The urine sediment is also very helpful in identifying other 
potential cause of intrinsic renal disease such a glomerulonephritis or vasculitis in which 
proteinuria, dysmorphic red blood cells, and red blood cell casts may be seen (32).  
Treatment of AKI is of course dependent on etiology and it remains primarily 
supportive.  Pre-renal AKI requires appropriate volume resuscitation while other forms of 
AKI, including ATN, are often harmed by volume overload and require instead 
electrolyte repletion, avoidance of renal toxins, and RRT in cases of refractory 
hyperkalemia, volume overload, metabolic acidosis or uremia.  Unfortunately, despite our 
improved understanding of AKI and advances in supportive care, mortality from the 
disease has remained at around 50% for the past four decades (33).  Additionally, 
morbidity from AKI remains significant with some studies indicating as much as a three-
fold greater risk for developing ESRD over the course of a decade when compared to 
controls (34).     
One avenue towards improving outcomes in AKI lies in finding a more accurate 
and sensitive biomarker that will enable earlier detection of kidney injury and thus allow 
for administration of potentially therapeutic interventions before lasting damage occurs.  
Research in this field has thus far focused on several potential biomarkers of kidney 
disease such as cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), kidney 
injury molecule-1 (KIM-1), and interleukin-18 (IL-18), initially identified via microarray 
analysis and genomics (35).  As we await large, prospective multicenter trials to 
determine these biomarkers’ ultimate clinical utility and application, the search continues 
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for other laboratory tests that will aid in early detection of AKI.  Also, though the AKIN 
stage has been shown to correlate with eventual outcomes in AKI, the need for 
identifying additional prognostic factors besides creatinine and urine output remains, as 
this would help individualize therapy in AKI, determining appropriate aggressiveness of 
intervention required and aiding in long-term planning of patient care (36, 37).  
Urine Microscopy’s Role in the Study of Acute Kidney Injury 
Though tradition and consensus have suggested that urine microscopy and other 
urinary indices can provide important clues to the differential diagnosis of acute kidney 
injury, there is little evidence to support these widely held beliefs.  In fact, in a systematic 
review of the literature of septic AKI, Bagshaw et al found that that no single measure of 
urinary biochemistry, derived index, or pattern on microscopy could be used reliably to 
diagnose AKI or predict the clinical course of AKI in these patients (38).  A follow-up 
review by the same group then reviewed experimental studies that utilized urinary 
findings to monitor the progress of septic AKI in animal models, concluding that 
sustained oliguria, decline in glomerular filtration, and evidence of sodium retention by 
UNa <20 mmol/L, FeNa <1%, and Uosm >400 mosm/L appeared to be the most reliable 
indices of worsening AKI and that there were not enough studies that used urinary 
microscopy in this particular review for its utility to be determined (39).  The limitations 
of both of these reviews were that the studies examined in each were far too heterogenous 
for any quantitative analysis to be performed.  Also, as pointed out by the authors 
themselves, many of the studies reviewed had major design flaws including small study 
populations and retrospective design, failure to include a control group, a heterogenous 
patient population, failure to account for potential confounding factors, variable timing in 
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measurements, and inconsistent reporting of several individual urinary tests (38).  Thus, 
the question of the utility of urinary indices, including microscopy in the study of AKI, is 
still very much unsettled, and several studies in the existing body of literature have 
attempted to prove that urine microscopy can in fact hold many useful clues to 
differential diagnosis and prognosis in AKI. 
In an effort to firmly establish the importance of urine microscopy as a validated 
diagnostic tool in AKI, a study by Perazella et al in 2008 showed that urinary microscopy 
findings could be used in conjunction with a clinically determined pretest probability to 
quite definitively distinguish pre-renal AKI from ATN.  In patients with a high pretest 
probability of ATN, any casts or renal tubular epithelial cells (RTECs) resulted in very 
high positive predictive value (100%) and low negative predictive value (44%) for a final 
diagnosis of ATN.  Conversely, the negative predictive value of the absence of casts or 
RTECs in patients with low pretest probability of disease was 91% (40).  This study 
helped establish likelihood ratios that would enable clinicians to calculate posttest 
probability of either ATN or prerenal azotemia once they have estimated the pretest 
probability of either cause of AKI (41).  A study by Marcussen et al also examined this 
link between urine microscopy and the diagnosis of AKI.  They found a significantly 
higher number of collecting duct cells and casts (p <0.05 and p<0.03, respectively) in the 
urine of 34 patients with ATN when compared to the 17 patients with non-ATN AKI 
(42).  Similarly, a much earlier study by Gay et al analyzed the urine sediment in children 
who had AKI of varying etiologies and concluded that the cause of AKI could be 
determined by the urine sediment results, sometimes prompting an alteration of a 
previously made diagnosis (43).   
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 Other studies have focused on the potential role of urine microscopy in predicting 
severity of AKI and thus subsequent outcomes.  Schentag et al conducted daily 
examinations of the urine of 154 critically ill patients in order to compare cast excretion 
among sick patients, sick patients given aminoglycosides, and sick patients with 
aminoglycoside nephrotoxicity.  Their results indicated that cast counts in the 30 
nephrotoxic patients were 625 ± 364, significantly higher than either ICU patients who 
had not received aminoglycosides (44 ± 51 casts) or those who had been given 
aminoglycosides without a significant rise in serum creatinine (153 ± 196 casts).  In some 
cases, cast counts began rising significantly as early as 9 days before serum creatinine 
first rose, indicating that urine microscopy can be an early predictor of worsening AKI 
(44).   
In a study of patients with non-AKI renal disease, Gyory et al evaluated the 
correlation between the severity of pathologic changes found on renal biopsy with the 
number of casts excreted in the urine prior to biopsy, concluding that there was in fact a 
significant positive correlation (r = 0.630, p <0. 01) (45).   
More recent work has further established a strong link between findings on urine 
microscopy and outcomes in AKI.  In the previously mentioned study by Marcussen et al, 
they found that in addition to distinguishing ATN from other causes of AKI, urine 
sediment results also predicted outcomes, as patients who would eventually require 
dialysis consistently had higher numbers of renal cells and casts in their urine sediment 
(42).  Chawla et al in their 2008 study established a cast scoring index (CSI) based on the 
numbers of granular and epithelial cell casts in the urine to improve standardization of 
reporting urine microscopy results and to determine whether a correlation existed 
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between a higher CSI and worse outcomes such as death or need for dialysis.  Though the 
study was quite small and only included 18 patients, the patients that had worse outcomes 
had a higher CSI when compared with patients that recovered renal function (2.55 ± 0.93 
vs. 1.57 ± 0.79, p = 0.04). The ROC area under the curve for CSI to diagnose worsening 
was 0.79 (46). 
Recent work done by Perazella et al has attempted to prospectively study the 
relationship between urine microscopy findings at the time of nephrology consultation 
and clinical outcomes in AKI.  Using a urinary sediment scoring system based on the 
number of RTECs and granular casts, they graded the urine of 197 patients with either 
pre-renal AKI or ATN and found that their urinary scoring system was significantly 
associated with increased risk of worsening AKI (adjusted relative risk: 7.3; for 
worsening with score of ≥3 versus score of 0) and was more predictive than AKI 
Network stage at the time of consultation (47).  
Even electron microscopy has been used in this endeavor in studies by Mandal et 
al (48-50).  Urinary sediments from 31 patients with oliguric acute tubular necrosis 
(ATN) were divided into three categories based on the severity of ultrastructural changes 
observed in the RTECs.  Type I cells showed signs of severe and significant damage with 
an abundance of necrotic cells and cellular fragments, disrupted plasma membranes, 
dysmorphic mitochondria, and absent nuclei.  Type II sediments displayed the mildest 
changes and were composed of a relatively homogenous population of modestly damaged 
RTECs.  In these sediments, cellular and subcellular organelle membranes remained 
largely intact, and they contained normal appearing mitochondria and nuclei.  Type III 
sediments were quite heterogenous and displayed changes intermediate to those seen in 
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the Type I and Type II sediments.  In this study, a correlation was found between the 
sediment type and the severity of the clinical illness (p <0.05) with only 2 out of 11 
patients with Type I sediment surviving while 7 of the 8 patients with Type II sediment 
survived (48).  Despite the potential advantages of EM, it remains prohibitively 
expensive to incorporate into routine practice. 
Of course, some of these studies have flaws like small sample sizes, absence of 
control groups, and inconsistency in when the urine microscopy was performed in 
relation to the onset of AKI (see Table 4).  Nonetheless, taken together, they support the 
notion that urine microscopy can play an important role in determining the cause and 
subsequent outcomes of AKI.  Though biomarkers currently under investigation show 
much promise in improving our understanding of AKI, urine microscopy continues to be 
a simple, inexpensive, and potentially powerful way of assessing kidney dysfunction.   
Table 4 Summary of studies reviewed  
Author Goals  Population Results Limitations





evidence of renal 
disease 
 22 patients 
undergoing 
renal biopsy 
 Microscopy on 
day of biopsy 





change on biopsy 
with strong 
predictive value 
 Small population 
 No details on 
types of casts 
studied 
Mandal 1985 Assess whether 
ultrastructural 
changes on TEM 
corresponded to 
outcomes in AKI 










 Small population 
 TEM difficult to 
translate to 
routine practice 
Gay 1987 Determine utility 
of microscopy in 
differential 
diagnosis of AKI 
 31 children with 
AKI 
 Microscopy 







 Small population 
 No details about 
pattern of casts in 
the urine 
Schentag 1987 Assess the value 
of quantitative 
cast excretion as 
a marker of AKI 
 154 ICU 




 Cast counts 
were highest in 
those with AG 
toxicity 
 In some cases, 
cast count rose 
prior to 
creatinine rise 




 Only studied AG-
related AKI 
 











weeks of peak 
creatinine 
of cells and 
casts in patients 
with ATN than 
those with non-
ATN AKI 
 Higher numbers 












proven to be 
useful in 
diagnosis of AKI 
Meta-analysis of 
27 studies that 
recorded urinary 
indices in patients 
with septic AKI 
























27 studies of  
experimental 




in GFR and 









 Heterogeneity of 
studies 
 Difficult to 
extrapolate from 
animal models to 
humans 
Chawla 2008  Devise a more 
uniform way to 
evaluate urine  
 Determine if 
their score was 
predictive of 
outcome 
 30 patients with 
ATN though 
outcomes were 
only looked at in 
18 
 Microscopy at 
time of consult 
 Score was 
highly 
reproducible 





those that did  
 Small population 
 
Perazella 2008 Assess utility of 
microscopy in 
differential 
diagnosis of AKI 
 267 hospitalized 
patients with 
AKI 
 Microscopy at 
time of consult 
 
   
Presence or 
absence of casts 









 Observers were 






Perazella 2010 Determine 
whether urine 
microscopy score 
was predictive of 
outcome 
 197 hospitalized 
patients with 
AKI 
 Microscopy at 
time of consult 









 Observers were 
not blinded to 
clinical data 
 Microscopy 
performed at time 
of consult 
 
AG = aminoglycoside, AKI = Acute Kidney Injury, ATN = Acute Tubular Necrosis, GFR = glomerular filtration rate, ICU = 
Intensive Care Unit, Na = sodium, TEM = Transmission Electron Microscopy  
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GOALS OF THIS STUDY 
Current research in the study of AKI is focused on the search for better ways of 
identifying incipient renal disease and for prognostic factors that can help guide 
treatment.  Based on a small but consistent body of literature, it appears that in this 
endeavor, urine microscopy can be of significant utility.  In particular, much work has 
been done in establishing a correlation between findings on urine microscopy and 
outcomes in AKI, but the timing of urine microscopy in these studies has been variable or 
late in the course of the disease (ie at the time of nephrology consultation).  This study 
hopes to build on earlier work by prospectively analyzing urine samples collected earlier 
in the evolution of AKI when information about prognosis is perhaps most helpful and 
most needed.  In particular, we attempted to ascertain whether urine microscopy results at 
the time of first clinical AKI diagnosis correlated with worse outcomes.  If so, urine 
microscopy results can potentially be used to determine prognosis at a very early stage of 
disease and thus help direct the treatment of patients with AKI.   
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METHODS 
Patients admitted to Yale-New Haven Hospital from July 2008 to August 2009 were 
prospectively screened for inclusion in this study.  Patients with end-stage kidney disease 
or kidney transplant, those discharged within 24 hours of enrollment, those transferred 
from another institution, or those whose urine samples could not be analyzed within four 
hours of collection were excluded from the study.  All adult patients on medical and 
surgical floors and in intensive care units (ICUs) were screened for AKI on a daily basis 
using electronic medical records to follow trends in serum creatinine (SCr).  Real-time 
SCr graphs were utilized to detect an increase of 0.3 mg/dL or 50% over 48 hours from a 
previously determined baseline.  For patients who had AKI within 48 hours of admission, 
baseline SCr was determined from outpatient medical records. For those who developed 
AKI later in their hospital stay, baseline SCr was defined as the admission SCr.  For the 
few patients whose admission SCr was higher than the SCr at enrollment, then the lowest 
stable SCr within two days before the AKI episode was used as the baseline.  Waiver of 
written consent permitted the collection of de-identified patient information and urine 
samples.   
Upon enrollment, a 10mL urine sample was obtained either from catheter tubing 
or from clean catch samples. Samples were centrifuged for 5 minutes at 1500 rpm.  The 
supernatant was decanted, leaving a 0.5 ml residual.  The pellet was then resuspended 
with a pipette.  1 drop of sediment was pipetted onto a glass slide and a coverslip was 
placed on top.  The slide was analyzed under standard light microscopy at low power 
(10x), high power (40x), and polarization when crystals were identified. Red and white 
blood cells, RTE cells, RTE casts, granular casts, and hyaline casts were identified 
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according to standard definitions and their numbers were recorded (40) (see Figure 1).  
Additionally, the urinary sediment scoring system designed by Perazella et al was used to 
facilitate subsequent analysis (47).  As demonstrated in Table 5, the score was calculated 
by summing the points that corresponded to the numbers of RTE cells and/or granular 
casts in the sediment.  All investigators who performed the microscopy were instructed 
by faculty from the Section of Nephrology at Yale through didactic sessions and hands-
on demonstrations on the proper identification of important cellular elements in the urine.   
Patients were followed until discharge from the hospital, resulting in the 
collection of demographic data (ie age, gender, and race), as well as information on the 
patients’ relevant comorbidities such as diabetes, hypertension (HTN), peripheral 
vascular disease (PVD), congestive heart failure (CHF), coronary artery disease (CAD), 
and chronic kidney disease (CKD).  FeNa, urine dipstick analysis and serum creatinine 
concentrations (baseline, peak, and at time of discharge) were also recorded when 
available.  Primary and secondary outcomes data collected on enrolled patients included 
in-hospital initiation of dialysis, death during hospitalization, and need for nephrology 
consultation.  Etiologies of AKI were adjudicated retrospectively via chart review.  Acute 
tubular necrosis was defined as AKI that did not respond to fluid resuscitation (ie Scr 
remained stable or increased) within 48 hours of treatment.  Prerenal was defined as AKI 
that responded to fluid resuscitation with an improvement of Scr within 48 hours of 
treatment.  All other diagnosis were recorded as “other.”  Results were recorded on a data  
Table 5 Urine sediment scoring system based on numbers of granular casts and RTE cells 
  Granular casts (per LPF)
RTE cells        
(per HPF) 
0           
(0 points) 
1-5       
(1 point) 
≥6         
(2 points) 
0 (0 points) 0 1 2 
1-5 (1 point) 1 2 3 
≥6 (2 points) 2 3 4 
Adapted from Perazella et al (47) 
 24
 
Figure 1 Images of microscopy findings 
from our study patients 
a) RTE cell (high-power view)  
b) Granular casts (low-power view)  















collection form and subsequently entered into TrialDB, an online database.   
The primary outcome was the composite outcome of “worsened AKI,” defined by 
an increase in AKIN stage at the time of peak serum creatinine or in-hospital death. 
Categorical variables were compared via χ2 analyses and continuous variables were 
compared using one-way ANOVA.  All statistical analyses were performed using SPSS 
and SAS.  The study design and protocol was approved by the Human Investigation 
Committee at Yale University.    
Patricia Peter and Isaac Hall, under the guidance of Chirag Parikh, were involved 
in establishing study design and methodology.  Patricia Peter, Madiha Koraishy, and 
Isaac Hall contributed to data acquisition and recording of laboratory values and hospital 
course information, in addition to urine sample collection and microscopy evaluation.  
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Table 6 Baseline characteristics of study population by worsened AKI 
Characteristic N (N %)A or       
mean ± SD       
(N=165) 
WorsenedB or 
died        
(N=49) 
Did not worsen 
or die            
(N=116) 
PC
Age (years) 66.1 ±16.2 67.5 ±15.1 65.4 ±16.7 0.461 
Gender    0.316 
     Male 94 (57) 25 (51) 69 (60) 
     Female 71 (43) 24 (49) 47 (41) 
Race    0.551 
     White 126 (76) 37 (76) 89 (77) 
     Black 28 (17) 10 (20) 18 (16) 
     Other 11 (7) 2 (4) 9 (8) 
Body Mass Index 29.4 ±7.7 30.4 ±8.4 29 ±7.3 0.294 
Baseline ScrD 1.3 ± 0.5 1.3 ± 0.6 1.3 ± 0.4 0.832 
Baseline GFR 65 ± 28 66 ± 31 64 ± 27 0.683 
Baseline CKD stage    0.050 
     Stage 1 (GFR≥ 90) 29 (18) 9 (18) 20 (17) 
     Stage 2 (GFR 60-89.9) 51 (31) 19 (39) 32 (28) 
     Stage 3 (GFR 30-59.9) 74 (45) 15 (31) 59 (51) 
     Stage 4-5 (GFR 0-29.9) 11 (7) 6 (12) 5 (4) 
Past Medical History     
     Known CKD 44 (27) 12 (26) 32 (28) 0.799 
     Hypertension     114 (69) 32 (65) 82(71) 0.445 
     Diabetes                   67 (41) 23 (47) 44 (38) 0.301 
     CHF                                     66 (40) 19 (39) 47 (41) 0.835 
     CAD    68 (41) 17 (35) 51 (44) 0.312 
     Cirrhosis 14 (9) 5 (10) 9 (8) 0.606 
     COPD 33 (20) 8 (16) 25 (22) 0.443 
     Stroke 23 (14) 7 (15) 16 (14) 0.895 
     Dementia 18 (11) 6 (13) 12 (10) 0.655 
     Active cancer 37 (22) 18 (38) 19 (16)  0.003*
     OSA 18 (11) 4 (8) 14 (12) 0.486 
     # of Comorbidities    0.323 
           None 10 (6) 2 (4) 8 (7) 
           One 19 (12) 3 (7) 16 (14) 
           Two or more 129 (78) 40 (89) 89 (79) 
Tobacco use    0.214 
      Never 81 (49) 25 (57) 56 (53) 
      Prior 35 (21) 13 (30) 22 (21) 
      Current 33 (20) 6 (14) 27 (26) 
Enrollment location    0.032*
      ICU 90 (55) 33 (67) 57 (49) 
      Floor 75 (46) 16 (33) 59 (51) 
AKI Stage at enrollment    0.001*
     Stage 1 139 (84) 34 (69) 105 (91) 
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     Stage 2 26 (16) 15 (31) 11 (10) 
A Numbers may not sum to totals due to missing data; Row and column percentages for totals may not sum to 100% due 
to missing data and rounding. B Worsened AKI is defined as progression to a higher AKI stage at time of peak serum 
creatinine when compared to AKI stage on day of enrollment. C P-values obtained from analysis of variance F-test 
(continuous variable) or χ2 test (categorical variable).  D Scr = Serum creatinine. Baseline Scr = Admission Scr. If 
admission Scr is missing or admission Scr is greater than Scr on the day of enrollment (day 0), then baseline Scr = 
minimum of Scr collected two days before enrollment (day -2 and day -1). 
GFR = Glomerular Filtration Rate, CKD = Chronic Kidney Disease, CHF = Congestive Heart Failure, CAD = Coronary Artery 
Disease, COPD = Chronic Obstructive Pulmonary Disease, OSA = Obstructive Sleep Apnea, ICU = Intensive Care Unit
 
165 patients admitted to Yale-New Haven Hospital from July 2008 to August 
2009 were prospectively enrolled in this study on the first day of their AKI as determined 
by standard serum creatinine criteria (see Methods section above).  115 patients were 
ultimately diagnosed with prerenal AKI, 35 with ATN, and the remaining 15 with other 
causes of AKI including allergic interstitial nephritis, hepatorenal syndrome, obstructive 
nephropathy, contrast nephropathy, lupus nephritis, and IgA nephropathy.   
49 of these patients experienced the composite outcome of worsened AKI or 
death.  Those who worsened were more likely to have an active cancer diagnosis 
(p<0.003), to be located in the ICU (p<0.032), and to have a higher AKI stage at the time 
of enrollment (p<0.001) (see Table 6).  Otherwise, no significant differences existed in 
age, gender, or comorbidities between the two populations.  Also of note, there were no 
differences in baseline kidney function prior to injury between the two populations 
whether measured as serum creatinine, GFR, or CKD stage.     
Patients who worsened were more likely to experience secondary outcomes such 
as oliguria or anuria during their hospitalization (p<0.001), higher peak serum creatinines 
(3.2 ± 1.5 versus 1.9 ± 0.6, p<0.001), higher discharge serum creatinines (2.0 ± 1.4 versus 
1.4 ± 0.5, p = 0.001), and longer lengths of stay (32.4 ± 33.6 versus 18.2 ± 24.5, p = 
0.003) (see Table 7).  The average AKI stage at peak serum creatinine was 2.4 for those 
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who worsened and 1.1 for those that did not.  Though one would perhaps expect that 
patients with a higher peak AKI stage would have a greater incidence of worsening or  
death, no such dose-dependent relationship was observed.  Instead there was a relatively 
even distribution of patients, with 31% of worsening patients peaking at Stage 1, 22% 
peaking at Stage 2, 22% peaking at Stage 3, and 25% peaking at Stage 3 and requiring 
dialysis.  Also, though differences in AKI duration between the two groups did not 
achieve statistical significance, patients with worse outcomes had AKI that lasted for 2.7 
more days, on average, than those that did not worsen.  Patients in the “worsened” group 
were also more likely to require a nephrology consultation over the course of their 
hospital stay and to ultimately be diagnosed with ATN.   
 
Table 7 Secondary outcomes in the study population 
  
Secondary Outcome N (N %) or            
mean ± SD  
(N=165)      
WorsenedA or 
died     
(N=49)   
Did not worsen 
or die 
(N=116)           
PB
Peak ScrC 2.3 ± 1.1 3.2 ± 1.5 1.9 ± 0.6 <.001*
AKI Stage at peak Scr 1.5 ± 0.9 2.4 ± 1.2 1.1 ± 0.3 <.001*
     Stage 1 120 (73) 15 (31) 105 (91) 
     Stage 2 22 (13) 11 (22) 11 (10) 
     Stage 3 11 (7) 11 (22) 0 (0) 
     Stage 3 –Dialysis 12 (7) 12 (25) 0 (0) 
Discharge Scr 1.5 ± 0.7 2.0 ± 1.4 1.4 ± 0.5 0.001*
Oliguria/Anuria                       26 (16) 16 (40) 10 (10) <.001*
Nephrology consult 35 (21) 23 (47) 12 (10) <.001*
AKI Diagnosis    <0.001*
     Prerenal 115 (21) 20 (41) 95 (82) 
     ATN 35 (70) 26 (53) 9 (8) 
     Other 15 (9) 3 (6) 12 (10) 
Length of AKI 5.1 ± 8.3 7.3 ± 11 4.6 ± 8 0.249 
Length of stay 22.5 ± 28.2 32.4 ±33.6 18.2 ±24.5 0.003*
A Worsened AKI is defined as progression to a higher AKI stage at time of peak serum creatinine when compared to AKI 
stage on day of enrollment.  B P-values obtained from analysis of variance F-test (continuous variable) or χ2 test 
(categorical variable).  C Scr = Serum creatinine 





The microscopy results shown in Table 8 reveal a significant association between 
worsening AKI and a greater number of granular casts in the urine (p = 0.027).  Though 
no association was found between worsening and the number of RTE cells individually, a 
higher overall microscopy score was found in the sediment of patients who worsened or 
died (p = 0.046).  Interestingly, the microscopy score was related to worsening with a 
dose-dependent trend, as 6% of patients who worsened had a score of 0, 25% had a score 
of 1, and 49% had a score of 2.  This trend did not hold at microscopy scores of 3 or 
greater, however, which only occurred in 20% of patients who worsened. 
Table 8 Microscopy results by worsened AKI 
Characteristic N (N %)A             
or mean ± SD       
(N=165) 
WorsenedB or 
died            
(N=49) 
Did not worsen 
or die           
(N=116) 
PC
RTE cells/HPF    0.261 
0 35 (21) 7 (14) 28 (24) 
      1-5 121 (73) 38 (78) 83 (72) 
WBCs/HPF    0.372 
0 42 (26) 9 (18) 33 (28) 
      1-5 82 (50) 27 (55) 55 (47) 
6-20 27 (16) 7 (14) 20 (17) 
RBCs/HPF    0.424 
0 44 (27) 10 (20) 34 (29) 
      1-5 70 (42) 20 (41) 50 (43) 
6-20 27 (16) 11 (22) 16 (14) 
RTE cell casts/LPF    0.234 
0 112 (68) 30 (61) 82 (71) 
      1-5 53 (32) 19 (39) 34 (29) 
Granular casts/LPF    0.027*
0 58 (35) 11 (22) 47 (41) 
      1-5 95 (58) 32 (65) 63 (54) 
      6-20 10 (6) 4 (8) 6 (5) 
WBC casts/LPF    0.580 
0 145 (88) 42 (86) 103 (89) 
      1-5 20 (12) 7 (14) 13 (11) 
Hyaline casts/LPF    0.942 
0 69 (42) 20 (41) 49 (42) 
      1-5 60 (36) 17 (35) 43 (37) 
      6-20 29 (18) 10 (20) 19 (16) 
Microscopy ScoreD    0.046*
0 21 (13) 3 (6) 18 (16) 
      1 51 (31) 12 (25) 39 (34) 
      2 74 (45) 24 (49) 50 (43) 
      ≥3 19 (12) 10 (20) 9 (8) 
A Numbers may not sum to totals due to missing data; Row and column percentages for totals may not sum to 100% due 
to missing data and rounding. B Worsened AKI is defined as progression to a higher AKI stage at time of peak serum 
creatinine when compared to AKI stage on day of enrollment. C P-values obtained from analysis of variance F-test 
(continuous variable) or χ2 test (categorical variable).  D Microscopy score calculated from Table 5.  
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 Subgroup analysis was subsequently performed to further investigate the 
relationship between microscopy scores on day one of AKI and eventual outcomes.  
Patients with a higher microscopy score on the first day of their AKI were significantly 
more likely to suffer the composite outcome of worsening AKI or death (p = 0.046) and 
more likely to eventually require a nephrology consultation during the course of their 
admission (p = 0.010), both associations occurring in a dose-dependent manner (see 
Table 9).  The incidence of worsened AKI or death rose consistently from 14% of 
patients with a microscopy score of 0, 24% with a score of 1, 32% with a score of 2, and 
finally to 53% in patients with scores of greater than or equal to 3.  A similar pattern was 
found with need for nephrology consultation during hospitalization (with incidences of 
worsening at 0%, 18%, 26%, and 37% corresponding to scores of 0, 1, 2, and greater than 
or equal to 3, respectively).  Though there was no statistically significant association 
between microscopy score and the individual outcomes of higher AKI stage at peak 
serum creatinine, dialysis, death, or ATN diagnosis, there was a noticeable trend of 
increased incidence of death with successively higher microscopy scores (5%, 16%, 23%, 
and 32% at scores of 0, 1, 2, and 3 or greater, respectively), a relationship made clear in 



















0 (n=21) 3 (14) 3 (14) 0 (0) 1 (5) 0 (0) 3 (14) 15 (71) 3 (14) 
1 (n=51) 12 (24) 9 (18) 4 (8) 8 (16) 9 (18) 8 (16) 40 (78) 3 (6) 
2 (n=74) 24 (32) 10 (14) 4 (5) 17 (23) 19 (26) 15 (20) 51 (69) 8 (11) 
≥3 (n=19) 10 (53) 8 (42) 4 (21) 6 (32) 7 (37) 9 (47) 9 (47) 1 (5) 
PC = 0.046* 0.055 0.078 0.117 0.010* 0.119 
All values are reported as N (N%). A Microscopy score calculated from Table 5. B Worsened AKI is defined as progression to 
a higher AKI stage at time of peak serum creatinine when compared to AKI stage on day of enrollment. C P-values obtained 
from Fisher’s exact test using χ2 analysis.  
AKI = acute kidney injury, ATN = acute tubular necrosis, SCr = serum creatinine












































Despite the wealth of research devoted to the field, AKI remains a prevalent 
disease that has seen little improvement in outcomes over the past several decades.  In 
response, current research has focused on identifying diagnostic tests that will allow for 
earlier detection of AKI, more accurate determination of etiology, and better prediction of 
morbidity and mortality from the disease.  In this study, we examine the potential value 
of urine microscopy in achieving at least some of these goals. Our results show that 
higher numbers of granular casts and RTE cells in the urine sediment of hospitalized 
patients (as captured in our microscopy score) on the first day of AKI are associated with 
increased incidence of worsening AKI or death in a dose-dependent fashion.  These 
results build on earlier work from our group in reinforcing the potential utility of urine 
microscopy in better evaluating and risk stratifying patients with AKI at an early stage of 
their disease course (40, 41, 47).   
Predicting outcomes in AKI has to potential to help guide management as more 
aggressive interventions could be conducted earlier on patients who are thought to have a 
poorer prognosis.  Additionally, prognostic information would help to better inform 
physicians about the likelihood that their patients will develop more serious long-term 
sequela of AKI, helping both patients and their providers to prepare for such 
consequences.  Current efforts to risk stratify patients with AKI rely heavily on 
established staging criteria since a stepwise increase in risk of death going from Risk to 
Injury to Failure in the RIFLE criteria has been studied and validated in both small 
studies and systematic reviews (36, 37, 51).  However, the staging criteria are imperfect 
in predicting outcomes.  Firstly, there is a paucity of prospective data supporting the 
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predictive ability of these staging systems (only about 2% of patients studied were 
featured in prospective studies) (52).  Also, since these criteria were initially designed to 
simply standardize definitions of AKI, they focus solely on markers of kidney function 
without consideration for extrinsic factors that might affect outcomes (ie hospital 
complications, age, etc) (52).  Previous attempts at devising AKI-specific severity scores 
to aid in the determination of prognosis have included variables focused primarily on age, 
gender, and a variety of hospital course events such as mechanical ventilation, 
hypotension, sepsis, heart failure, or oliguria with some contributions from biomarkers 
such as creatinine or urea.  Many of these scores have not been externally validated for 
their ability to accurately predict outcome, and so the search continues for better means 
of risk-stratifying patients with AKI  (53).  Our results suggest that as part of the 
continued effort to identify different stages of AKI severity and to better predict 
subsequent outcomes, urine microscopy should be considered as a potentially valuable 
adjunct to clinical and demographic characteristics.   
In addition to finding better methods for predicting outcomes, much research in 
the field of AKI has focused on discovering biomarkers that will more quickly and 
accurately diagnose AKI early in the course of the disease.  The current staging systems 
rely on serum creatinine as a marker of kidney dysfunction which is believed to be an 
imperfect and late indicator of true renal injury.  This potential delay in diagnosis and 
treatment of AKI could be contributing in large part to the poor outcomes in this disease 
(54).  Serum creatinine is influenced by many factors extrinsic to renal injury such as age, 
muscle mass, gender, medications and hydration status.  Additionally, serum creatinine 
requires a steady-state equilibrium to accurately depict kidney function, something that is 
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often only achieved days after the initial insult.  Thus, this need for a more accurate and 
sensitive marker coupled with an improved understanding of the pathophysiology of 
kidney injury has led to the identification of many potential urinary biomarkers such as 
cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 
(KIM-1), and interleukin-18 (IL-18), several of which have showed much promise 
improving the accuracy of AKI diagnosis (29, 55-58).  As seen in our study, urine 
microscopy results even early in the course of AKI can provide valuable information 
about the ultimate degree of renal dysfunction, well before serum creatinine values reach 
their peak.  In this way, urine microscopy when combined with this new class of more 
powerful biomarkers will greatly enrich our ability to identify and characterize AKI 
earlier and more precisely. 
There are, of course, many limitations to this work.  One of the most crucial 
limitations is the absence of validation of the microscopy findings by an external 
reviewer and the failure to calculate inter-observer agreement on microscopy findings.  
Though the microscopy was conducted by investigators who were well-trained to 
examine urine, they were not subjected to an externally validated test of proficiency.  
However, the problem of observer bias was minimized in that at the time of microscopy, 
investigators were not aware that the study would be focused on associating microscopy 
results with patient outcomes.  Other flaws in study design include the absence of a group 
of patients without AKI to serve as a control and the relatively small sample size that 
experienced our composite outcome of worsening or death.  Additionally, given that 
creatinine is an admittedly imperfect marker of kidney injury, our microscopy results 
could in fact be capturing a later time point in the disease course than initially suspected.  
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Also, though the use of a logistic regression model would perhaps have been a more 
robust means of statistical analysis, our primary interest was to simply identify 
potentially significant associations between findings on urine microscopy and outcome.  
Other work in our lab hopes to go further by then using urine microscopy results along 
with other potential prognostic indicators such as urine biomarkers to create a powerful 
new model for understanding and characterizing AKI.   
Ultimately, the numbers of granular casts and RTE cells present in the urine of 
hospitalized patients on the first day of their AKI can be helpful in determining 
prognosis, including worsening of disease or in-hospital death.  A simple diagnostic tool 
that has long been well-regarded in the field of nephrology for its ability to provide 
impressive insight into the workings of the kidney, urine microscopy has the potential to 
expand its role as an invaluable clinical tool in the diagnosis of AKI to include predicting 
outcomes in AKI, likely as part of a panel of clinical measures and biomarkers.  As a 
component of current and future efforts to find markers that will improve diagnosis and 
outcome prediction in AKI, urine microscopy will hopefully continue to provide critical 
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